Citi DR Mid-Year 2018 Report

DR ACCESS PRODUCTS ABOUT CITI DEPOSITARY RECEIPT SERVICES INTERNATIONAL INVESTING TRENDS GLOBAL DR TRENDS *Signifies Citi DR program capital raising. Deals in bold italics signify a JOBS Act Deal. 1 Defined as capital raising at the time of listing of additional DR securities including rights offerings, and private placements. Data as of June 30, 2018. 2 Industry as defined by Bloomberg. Issuer Country Industry 2 USD Value (in Millions) BeiGene, Ltd.* China Biotechnology $800 Azul S.A.* Brazil Transportation $313 GDS Holdings Ltd. China Information Technology $292 Ascendis Pharma A/S Denmark Biotechnology $259 Cellectis S.A.* France Biotechnology $191 Talend S.A. France Software & Services $190 Bright Scholar China Commercial & Professional Services $190 Daqo New Energy China Materials $110 RISE Education Cayman Ltd. China Consumer Services $103 JinkoSolar Holding China Energy $75 Amarin Corp. plc* UK Biotechnology $70 DBV Technologies S.A.* France Biotechnology $68 Sequans Communications S.A. France Technology Hardware & Equipment $20 Celyad S.A.* Belgium Biotechnology $15 Nano Dimension Ltd. Israel Technology Hardware & Equipment $12 Ambow Education Holding Inc.* China Consumer Services $9 Grand Total $2,717 DR Follow-On Offerings 1 Source: Bloomberg and Depositary Data Interchange. 15 Citi Depositary Receipt Services Mid-Year 2018 Report